Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Q3 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript

Nov 02, 2020 / 12:00PM GMT
Release Date Price: kr208.35 (+1.50%)
Operator

Hello, and welcome to the Q3 2020 Novo Nordisk A/S Earnings Presentation. (Operator Instructions) Today I am pleased to present Karsten Munk Knudsen. Please go ahead with your meeting.

Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board

/- -

Thank you. And welcome to the Novo Nordisk third quarter results meeting. It's a pleasure to host this meeting, and a big thanks to Richard Vosser and JPMorgan for helping setting up this meeting. So for the meeting today, we have an update on our strategic aspirations, followed by COVID-19, commercial execution, innovation and therapeutic focus and financials. So organized in line with our strategic aspiration framework. We have planned it in a way. So the presentations will be followed by a Q&A session in the end.

As you all know, then statements around the future inherently are covered by a certain level of uncertainty. And hence, we remind you about this circumstance.

Moving on to our strategic aspirations. Then more

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot